Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial

Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink, Valentin Goede, Carmen Diana Herling, Paula Cramer, Petra Langerbeins, Julia Von Tresckow, Anja Engelke, Christian Maurer, Gabor Kovacs, Marco Herling, Eugen Tausch, Karl Anton Kreuzer, Barbara Eichhorst, Sebastian Böttcher, John F. Seymour, Paolo Ghia, Paula Marlton, Michael KnebaClemens Martin Wendtner, Hartmut Döhner, Stephan Stilgenbauer, Michael Hallek

Research output: Contribution to journalArticle

265 Citations (Scopus)

Abstract

Despite promising results with targeted drugs, chemoimmunotherapy with fludarabine, cyclophosphamide (FC), and rituximab (R) remains the standard therapy for fit patients with untreated chronic lymphocytic leukemia (CLL). Herein, we present the long-term follow-up of the randomized CLL8 trial reporting safety and efficacy of FC and FCR treatment of 817 treatment-näivepatientswithCLL.The primary end pointwas progressionfree survival (PFS). With a median follow-up of 5.9 years, median PFS were 56.8 and 32.9 months for theFCRand FCgroup (hazardratio[HR], 0.59; 95%confidence interval [CI], 0.50- 0.69, P<.001).Median overall survival (OS)was not reached for the FCRgroup and was 86.0 months for the FC group (HR, 0.68; 95% CI, 0.54-0.89, P 5 .001). In patients with mutated IGHV(IGHVMUT),FCRimprovedPFSandOScomparedwithFC(PFS:HR, 0.47; 95%CI, 0.33-0.68,P

Original languageEnglish
Pages (from-to)208-215
Number of pages8
JournalBlood
Volume127
Issue number2
DOIs
Publication statusPublished - Jan 14 2016

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Cyclophosphamide
Survival
Confidence Intervals
Therapeutics
Safety
Pharmaceutical Preparations
fludarabine

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Fischer, K., Bahlo, J., Fink, A. M., Goede, V., Herling, C. D., Cramer, P., ... Hallek, M. (2016). Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial. Blood, 127(2), 208-215. https://doi.org/10.1182/blood-2015-06-651125

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL : Updated results of the CLL8 trial. / Fischer, Kirsten; Bahlo, Jasmin; Fink, Anna Maria; Goede, Valentin; Herling, Carmen Diana; Cramer, Paula; Langerbeins, Petra; Von Tresckow, Julia; Engelke, Anja; Maurer, Christian; Kovacs, Gabor; Herling, Marco; Tausch, Eugen; Kreuzer, Karl Anton; Eichhorst, Barbara; Böttcher, Sebastian; Seymour, John F.; Ghia, Paolo; Marlton, Paula; Kneba, Michael; Wendtner, Clemens Martin; Döhner, Hartmut; Stilgenbauer, Stephan; Hallek, Michael.

In: Blood, Vol. 127, No. 2, 14.01.2016, p. 208-215.

Research output: Contribution to journalArticle

Fischer, K, Bahlo, J, Fink, AM, Goede, V, Herling, CD, Cramer, P, Langerbeins, P, Von Tresckow, J, Engelke, A, Maurer, C, Kovacs, G, Herling, M, Tausch, E, Kreuzer, KA, Eichhorst, B, Böttcher, S, Seymour, JF, Ghia, P, Marlton, P, Kneba, M, Wendtner, CM, Döhner, H, Stilgenbauer, S & Hallek, M 2016, 'Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial', Blood, vol. 127, no. 2, pp. 208-215. https://doi.org/10.1182/blood-2015-06-651125
Fischer, Kirsten ; Bahlo, Jasmin ; Fink, Anna Maria ; Goede, Valentin ; Herling, Carmen Diana ; Cramer, Paula ; Langerbeins, Petra ; Von Tresckow, Julia ; Engelke, Anja ; Maurer, Christian ; Kovacs, Gabor ; Herling, Marco ; Tausch, Eugen ; Kreuzer, Karl Anton ; Eichhorst, Barbara ; Böttcher, Sebastian ; Seymour, John F. ; Ghia, Paolo ; Marlton, Paula ; Kneba, Michael ; Wendtner, Clemens Martin ; Döhner, Hartmut ; Stilgenbauer, Stephan ; Hallek, Michael. / Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL : Updated results of the CLL8 trial. In: Blood. 2016 ; Vol. 127, No. 2. pp. 208-215.
@article{b0f6cc83511f4ba0adb5fc20e866d84a,
title = "Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial",
abstract = "Despite promising results with targeted drugs, chemoimmunotherapy with fludarabine, cyclophosphamide (FC), and rituximab (R) remains the standard therapy for fit patients with untreated chronic lymphocytic leukemia (CLL). Herein, we present the long-term follow-up of the randomized CLL8 trial reporting safety and efficacy of FC and FCR treatment of 817 treatment-n{\"a}ivepatientswithCLL.The primary end pointwas progressionfree survival (PFS). With a median follow-up of 5.9 years, median PFS were 56.8 and 32.9 months for theFCRand FCgroup (hazardratio[HR], 0.59; 95{\%}confidence interval [CI], 0.50- 0.69, P<.001).Median overall survival (OS)was not reached for the FCRgroup and was 86.0 months for the FC group (HR, 0.68; 95{\%} CI, 0.54-0.89, P 5 .001). In patients with mutated IGHV(IGHVMUT),FCRimprovedPFSandOScomparedwithFC(PFS:HR, 0.47; 95{\%}CI, 0.33-0.68,P",
author = "Kirsten Fischer and Jasmin Bahlo and Fink, {Anna Maria} and Valentin Goede and Herling, {Carmen Diana} and Paula Cramer and Petra Langerbeins and {Von Tresckow}, Julia and Anja Engelke and Christian Maurer and Gabor Kovacs and Marco Herling and Eugen Tausch and Kreuzer, {Karl Anton} and Barbara Eichhorst and Sebastian B{\"o}ttcher and Seymour, {John F.} and Paolo Ghia and Paula Marlton and Michael Kneba and Wendtner, {Clemens Martin} and Hartmut D{\"o}hner and Stephan Stilgenbauer and Michael Hallek",
year = "2016",
month = "1",
day = "14",
doi = "10.1182/blood-2015-06-651125",
language = "English",
volume = "127",
pages = "208--215",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL

T2 - Updated results of the CLL8 trial

AU - Fischer, Kirsten

AU - Bahlo, Jasmin

AU - Fink, Anna Maria

AU - Goede, Valentin

AU - Herling, Carmen Diana

AU - Cramer, Paula

AU - Langerbeins, Petra

AU - Von Tresckow, Julia

AU - Engelke, Anja

AU - Maurer, Christian

AU - Kovacs, Gabor

AU - Herling, Marco

AU - Tausch, Eugen

AU - Kreuzer, Karl Anton

AU - Eichhorst, Barbara

AU - Böttcher, Sebastian

AU - Seymour, John F.

AU - Ghia, Paolo

AU - Marlton, Paula

AU - Kneba, Michael

AU - Wendtner, Clemens Martin

AU - Döhner, Hartmut

AU - Stilgenbauer, Stephan

AU - Hallek, Michael

PY - 2016/1/14

Y1 - 2016/1/14

N2 - Despite promising results with targeted drugs, chemoimmunotherapy with fludarabine, cyclophosphamide (FC), and rituximab (R) remains the standard therapy for fit patients with untreated chronic lymphocytic leukemia (CLL). Herein, we present the long-term follow-up of the randomized CLL8 trial reporting safety and efficacy of FC and FCR treatment of 817 treatment-näivepatientswithCLL.The primary end pointwas progressionfree survival (PFS). With a median follow-up of 5.9 years, median PFS were 56.8 and 32.9 months for theFCRand FCgroup (hazardratio[HR], 0.59; 95%confidence interval [CI], 0.50- 0.69, P<.001).Median overall survival (OS)was not reached for the FCRgroup and was 86.0 months for the FC group (HR, 0.68; 95% CI, 0.54-0.89, P 5 .001). In patients with mutated IGHV(IGHVMUT),FCRimprovedPFSandOScomparedwithFC(PFS:HR, 0.47; 95%CI, 0.33-0.68,P

AB - Despite promising results with targeted drugs, chemoimmunotherapy with fludarabine, cyclophosphamide (FC), and rituximab (R) remains the standard therapy for fit patients with untreated chronic lymphocytic leukemia (CLL). Herein, we present the long-term follow-up of the randomized CLL8 trial reporting safety and efficacy of FC and FCR treatment of 817 treatment-näivepatientswithCLL.The primary end pointwas progressionfree survival (PFS). With a median follow-up of 5.9 years, median PFS were 56.8 and 32.9 months for theFCRand FCgroup (hazardratio[HR], 0.59; 95%confidence interval [CI], 0.50- 0.69, P<.001).Median overall survival (OS)was not reached for the FCRgroup and was 86.0 months for the FC group (HR, 0.68; 95% CI, 0.54-0.89, P 5 .001). In patients with mutated IGHV(IGHVMUT),FCRimprovedPFSandOScomparedwithFC(PFS:HR, 0.47; 95%CI, 0.33-0.68,P

UR - http://www.scopus.com/inward/record.url?scp=84955482904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955482904&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-06-651125

DO - 10.1182/blood-2015-06-651125

M3 - Article

C2 - 26486789

AN - SCOPUS:84955482904

VL - 127

SP - 208

EP - 215

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -